Optimum chemotherapy for ovarian cancer
- 1 January 2000
- journal article
- research article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 10 (s1) , 33-37
- https://doi.org/10.1046/j.1525-1438.2000.99508.x
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study GroupJournal of Clinical Oncology, 1999
- Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and CarboplatinJournal of Clinical Oncology, 1999
- Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 PatientsGynecologic Oncology, 1998
- ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancerThe Lancet, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian CancerNew England Journal of Medicine, 1995
- Carboplatin versus cisplatinAnnals of Oncology, 1993
- The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group studyGynecologic Oncology, 1992
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991